Limits...
Expression and clinicopathological significance of FSIP1 in breast cancer.

Zhang H, Luo M, Jin Z, Wang D, Sun M, Zhao X, Zhao Z, Lei H, Li M, Liu C - Oncotarget (2015)

Bottom Line: Expression of FSIP1 protein was significantly higher in breast cancer tissues compared to tumor-adjacent tissues (p = 0.001).Similarly, serum level of FSIP1 was higher in patients with recurrent and metastatic breast cancer compared to that of primary breast cancer (7, 713 ± 3, 065 vs. 4, 713 ± 3, 065 pg/ml, p = 0.003).Finally, patients with high FSIP1 expression showed a worse post-operative disease-specific survival (p = 0.024).

View Article: PubMed Central - PubMed

Affiliation: Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Hospital of Dalian Medical University, Dalian, China.

ABSTRACT

Aim: To investigate the clinicopathological significance of the expression of fibrous sheath interacting protein 1 (FSIP1) in breast cancer, serum samples, and wound fluid from patients with breast cancer.

Methods: Wound fluid and serum samples from female patients with primary breast cancer, recurrent and metastatic breast cancer, and benign tumors were analyzed for FSIP1 expression using ELISA. 286 paraffin-embedded surgical specimens from breast cancer patients with at least 5 years of follow-up were included for FSIP1 expression assay using immunohistochemistry.

Results: Expression of FSIP1 protein was significantly higher in breast cancer tissues compared to tumor-adjacent tissues (p = 0.001). Strong correlation was observed between FSIP1 expression and human epidermal growth factor receptor 2 (Her-2) or Ki67 expression in breast cancer (p = 0.027 and 0.002, respectively). Similarly, serum level of FSIP1 was higher in patients with recurrent and metastatic breast cancer compared to that of primary breast cancer (7, 713 ± 3, 065 vs. 4, 713 ± 3, 065 pg/ml, p = 0.003). Finally, patients with high FSIP1 expression showed a worse post-operative disease-specific survival (p = 0.024).

Conclusion: FSIP1 may play an important role in the tumorigenesis and invasion of breast cancer and is a potential biomarker for breast cancer diagnosis or prognosis.

No MeSH data available.


Related in: MedlinePlus

FSIP1 expression is associated with poor survival of breast cancer patientsAssociation between survival of 278 patients with invasive breast cancer and FSIP1 expression was estimated using Kaplan-Meier method and analyzed using log-rank test. (A) Patients with high FSIP1 expression had a worse postoperative disease-specific survival compared to the ones with negative FSIP1 expression (p = 0.022). Cumulative survival curves of FSIP1-positive and FSIP1-negative cancers according to ER, PR, Her-2, and Ki67 statuses are shown in Figure 5B–5E. Significant survival differences were observed between FSIP1-positive status and FSIP1-negative status in patients with ER-positive and Her-2-negative tumors (p = 0.016 and 0.009, respectively; Figures 5F and 5G).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496383&req=5

Figure 5: FSIP1 expression is associated with poor survival of breast cancer patientsAssociation between survival of 278 patients with invasive breast cancer and FSIP1 expression was estimated using Kaplan-Meier method and analyzed using log-rank test. (A) Patients with high FSIP1 expression had a worse postoperative disease-specific survival compared to the ones with negative FSIP1 expression (p = 0.022). Cumulative survival curves of FSIP1-positive and FSIP1-negative cancers according to ER, PR, Her-2, and Ki67 statuses are shown in Figure 5B–5E. Significant survival differences were observed between FSIP1-positive status and FSIP1-negative status in patients with ER-positive and Her-2-negative tumors (p = 0.016 and 0.009, respectively; Figures 5F and 5G).

Mentions: Patients with high FSIP1 expression in tumors tended to have worse post-operative disease-specific survival (p = 0.022; Figure 5A). When the data were analyzed according to the expression status of ER, PR, Her-2, and Ki67 in each tumor (Figure 5B–5E), significant survival differences were observed between FSIP1-positive status and FSIP1-negative status in patients with ER-positive and Her-2 negative tumors (p = 0.016 and 0.009, respectively; Figures 5F and 5G). The hazard ratio for death was 1.578 (95% CI, 1.062–2.345; p = 0.024) in the FSIP1-positive group (univariate analysis). After adjustment of seven baseline variables (age, tumor size, lymph node status, ER status, PR status, Her-2 status, and Ki67 status) by using Cox regression analysis, the hazard ratio was not significantly changed (hazard ratio, 1.383 [95% CI, 0.871–2.195]; p = 0.081; Table 4).


Expression and clinicopathological significance of FSIP1 in breast cancer.

Zhang H, Luo M, Jin Z, Wang D, Sun M, Zhao X, Zhao Z, Lei H, Li M, Liu C - Oncotarget (2015)

FSIP1 expression is associated with poor survival of breast cancer patientsAssociation between survival of 278 patients with invasive breast cancer and FSIP1 expression was estimated using Kaplan-Meier method and analyzed using log-rank test. (A) Patients with high FSIP1 expression had a worse postoperative disease-specific survival compared to the ones with negative FSIP1 expression (p = 0.022). Cumulative survival curves of FSIP1-positive and FSIP1-negative cancers according to ER, PR, Her-2, and Ki67 statuses are shown in Figure 5B–5E. Significant survival differences were observed between FSIP1-positive status and FSIP1-negative status in patients with ER-positive and Her-2-negative tumors (p = 0.016 and 0.009, respectively; Figures 5F and 5G).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496383&req=5

Figure 5: FSIP1 expression is associated with poor survival of breast cancer patientsAssociation between survival of 278 patients with invasive breast cancer and FSIP1 expression was estimated using Kaplan-Meier method and analyzed using log-rank test. (A) Patients with high FSIP1 expression had a worse postoperative disease-specific survival compared to the ones with negative FSIP1 expression (p = 0.022). Cumulative survival curves of FSIP1-positive and FSIP1-negative cancers according to ER, PR, Her-2, and Ki67 statuses are shown in Figure 5B–5E. Significant survival differences were observed between FSIP1-positive status and FSIP1-negative status in patients with ER-positive and Her-2-negative tumors (p = 0.016 and 0.009, respectively; Figures 5F and 5G).
Mentions: Patients with high FSIP1 expression in tumors tended to have worse post-operative disease-specific survival (p = 0.022; Figure 5A). When the data were analyzed according to the expression status of ER, PR, Her-2, and Ki67 in each tumor (Figure 5B–5E), significant survival differences were observed between FSIP1-positive status and FSIP1-negative status in patients with ER-positive and Her-2 negative tumors (p = 0.016 and 0.009, respectively; Figures 5F and 5G). The hazard ratio for death was 1.578 (95% CI, 1.062–2.345; p = 0.024) in the FSIP1-positive group (univariate analysis). After adjustment of seven baseline variables (age, tumor size, lymph node status, ER status, PR status, Her-2 status, and Ki67 status) by using Cox regression analysis, the hazard ratio was not significantly changed (hazard ratio, 1.383 [95% CI, 0.871–2.195]; p = 0.081; Table 4).

Bottom Line: Expression of FSIP1 protein was significantly higher in breast cancer tissues compared to tumor-adjacent tissues (p = 0.001).Similarly, serum level of FSIP1 was higher in patients with recurrent and metastatic breast cancer compared to that of primary breast cancer (7, 713 ± 3, 065 vs. 4, 713 ± 3, 065 pg/ml, p = 0.003).Finally, patients with high FSIP1 expression showed a worse post-operative disease-specific survival (p = 0.024).

View Article: PubMed Central - PubMed

Affiliation: Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Hospital of Dalian Medical University, Dalian, China.

ABSTRACT

Aim: To investigate the clinicopathological significance of the expression of fibrous sheath interacting protein 1 (FSIP1) in breast cancer, serum samples, and wound fluid from patients with breast cancer.

Methods: Wound fluid and serum samples from female patients with primary breast cancer, recurrent and metastatic breast cancer, and benign tumors were analyzed for FSIP1 expression using ELISA. 286 paraffin-embedded surgical specimens from breast cancer patients with at least 5 years of follow-up were included for FSIP1 expression assay using immunohistochemistry.

Results: Expression of FSIP1 protein was significantly higher in breast cancer tissues compared to tumor-adjacent tissues (p = 0.001). Strong correlation was observed between FSIP1 expression and human epidermal growth factor receptor 2 (Her-2) or Ki67 expression in breast cancer (p = 0.027 and 0.002, respectively). Similarly, serum level of FSIP1 was higher in patients with recurrent and metastatic breast cancer compared to that of primary breast cancer (7, 713 ± 3, 065 vs. 4, 713 ± 3, 065 pg/ml, p = 0.003). Finally, patients with high FSIP1 expression showed a worse post-operative disease-specific survival (p = 0.024).

Conclusion: FSIP1 may play an important role in the tumorigenesis and invasion of breast cancer and is a potential biomarker for breast cancer diagnosis or prognosis.

No MeSH data available.


Related in: MedlinePlus